A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors

SIMPLE SUMMARY: Fms-like tyrosine kinase type III (FLT3) inhibitors have been shown to induce significant clinical responses in patients with acute myeloid leukemia (AML) harboring FLT3 mutations. Responses to monotherapy and combination regimens are typically incomplete and transient, prompting the...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Gary Edward, Al-Rajabi, Raed, Uprety, Dipesh, Hamid, Anis, Williamson, Stephen K., Baranda, Joaquina, Mamdani, Hirva, Lee, Ya-Li, Nitika, Li, Li, Wang, Xingli, Dong, Xunwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177510/
https://www.ncbi.nlm.nih.gov/pubmed/37174019
http://dx.doi.org/10.3390/cancers15092553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177510/
https://www.ncbi.nlm.nih.gov/pubmed/37174019
http://dx.doi.org/10.3390/cancers15092553

Ejemplares similares